Dan Hicklin, Ph.D.
Dan Hicklin, Ph.D., joined MPM in 2014 subsequent to his successful role as President & Chief Scientific Officer and member of the Board of CoStim Pharmaceuticals (acquired by Novartis:NVS). He now serves as President and CEO of Potenza Therapeutics, an immuno-oncology company founded by MPM. Dan is also a board member of Tizona Therapeutics and Harpoon Therapeutics, two MPM portfolio companies.
From 2007 to 2013, Dan held several positions at Merck Research Laboratories (formerly the Schering-Plough Research Institute prior to its acquisition by Merck:MRK), including leading their Biologics Strategy for Oncology and the Immuno-modulation Discovery team. In these roles, he oversaw many oncology discovery and development projects including the portfolio of projects that Merck had developed in the rapidly advancing immuno-oncology area. During his career, Dan has complemented his scientific and leadership accomplishments with extensive experience across all phases of small molecule and biologics drug development.
Prior to joining Schering-Plough, Dan held several positions of increasing responsibility at ImClone Systems (acquired by Eli Lilly:LLY) from 1987 – 2007, including serving as Vice President of Experimental Therapeutics. His team at ImClone supported the development and FDA approval of the cancer treatment Erbitux® (Cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), necitumumab and other agents that were acquired by Eli Lilly. From 1996-1999, Dan was an Assistant Professor at New York Medical College. Dan received his Master’s and Ph.D. in Immunology from New York Medical College where he trained with Dr. Soldano Ferrone, and his B.S. from the University of Iowa.